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Abstract
Eighty percent of lung cancers originate as subtle premalignant changes in the airway mucosal epithelial
layer of bronchi and alveoli, which evolve and penetrate deeper into the parenchyma. Liquid-ventilation,
with perfluorocarbons (PFC) was first demonstrated in rodents in 1966 then subsequently applied as
lipid-encapsulated PFC emulsions to improve pulmonary function in neonatal infants suffering with
respiratory distress syndrome in 1996. Subsequently, PFC nanoparticles (NP) were extensively studied as
intravenous (IV) vascular-constrained nanotechnologies for diagnostic imaging and targeted drug delivery
applications.
Methods: This proof-of-concept study compared intratumoral localization of fluorescent paramagnetic
(M) PFC NP in the Vx2 rabbit model using proton (1H) and fluorine (19F) magnetic resonance (MR)
imaging (3T) following intratracheal (IT) or IV administration. MRI results were corroborated by
fluorescence microscopy.
Results: Dynamic 1H-MR and 19F-MR images (3T) obtained over 72 h demonstrated marked and
progressive accumulation of M-PFC NP within primary lung Vx2 tumors during the first 12 h post IT
administration. Marked 1H and 19F MR signal persisted for over 72 h. In contradistinction, IV M-PFC NP
produced a modest transient signal during the initial 2 h post-injection that was consistent circumferential
blood pool tumor enhancement. Fluorescence microscopy of excised tumors corroborated the MR
results and revealed enormous intratumor NP deposition on day 3 after IT but not IV treatment.
Rhodamine-phospholipid incorporated into the PFC nanoparticle surfactant was distributed widely
within the tumor on day 3, which is consistent with a hemifusion-based contact drug delivery mechanism
previously reported. Fluorescence microscopy also revealed similar high concentrations of M-PFC NP
given IT for metastatic Vx2 lung tumors. Biodistribution studies in mice revealed that M-PFC NP given IV
distributed into the reticuloendothelial organs, whereas, the same dosage given IT was basically not
detected beyond the lung itself. PFC NP given IT did not impact rabbit behavior or impair respiratory
function. PFC NP effects on cells in culture were negligible and when given IV or IT no changes in rabbit
hematology nor serum clinical chemistry parameters were measured.
Conclusion: IT delivery of PFC NP offered unique opportunity to locally deliver PFC NP in high
concentrations into lung cancers with minimal extratumor systemic exposure.
Key words: perfluorocarbon nanoparticle, MRI, drug delivery, lung cancer, intratracheal delivery.
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Introduction
Lung cancer is a leading cancer killer in both
men and women in the US, in recent years surpassing
breast cancer to become the leading cause of cancer
death in women. Worldwide, lung cancer is the most
common malignancy with ~1.8 million new cases and
1.6 million deaths annually [1]. Unfortunately, the
five-year survival rate for lung cancer (17.8%) is
notably less than for malignancies in the colon
(65.4%), breast (90.5%) and prostate (99.6%) [2]. While
patients diagnosed with early stage lung cancer have
~50% 5-year survival rate, the majority of individuals
are diagnosed late and are dead within a year. This
poor prognosis reflects the late presentation of clinical
disease symptoms, including cough, hemoptysis,
dyspnea, chest pain, or non-resolving pneumonia,
that prompt patients to seek medical attention. Most
lung cancer patients are diagnosed with non-small
cell lung cancer (NSCLC) (87%) with the remaining
malignancies attributed to small cell lung cancer [3].
80% of lung cancers originate as premalignant
changes in the airway mucosal epithelial layer of
bronchi and alveoli that progressively infiltrate into
the underlying parenchyma [4]. Clinically silent, these
small early lesions are typically beyond the resolution
of computed tomography (CT), magnetic resonance
(MR) or positron emission tomography/CT (PET/CT)
to detect effectively.18F-fluorodeoxyglucose PET
screening for lung cancer has a central role in disease
staging and therapeutic response assessment, but the
technique’s diagnostic sensitivity is only 83% [5, 6].
Optical imaging via bronchoscopy is effective for
evaluating premalignant epithelial mucosal lesions in
the central airways, but the invasive technique can
only interrogate six to seven generations of bronchi
with the thinnest bronchoscopes [7], leaving the outer
two-thirds of the lung inaccessible [8].
Traditional 1H MRI is plagued by respiratory
motion, air-tissue chemical-shift artifacts, and a low
prevalence of tissue water protons when imaging the
lung. However, promising advancements in MR
pulmonary imaging using simultaneous proton and
fluorine (1H/19F) MRI with ultrashort echo time
sequences (UTE) have been implemented for
preclinical models using clinical 3T MR scanners [9].
These emergent techniques optimized 19F imaging
and quantification by simultaneously acquiring
proton and fluorine image data, allowing the more
robust proton information to be used to optimize coil
and power parameters and to correct for motion
artifacts [9-11]. These technology advances have
brought the opportunity for high-resolution,
non-invasive, nonionizing MR imaging of the lung
closer to the clinic.
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Perfluorocarbon (PFC) nanoparticles (NP) are
~98% PFC with a high fluorine concentration of ~100
M [12]. Early preclinical and later clinical research
with PFCs involved liquid breathing, taking
advantage of the high oxygen-dissolving capacity of
PFCs to overcome respiratory distress in preterm
babies due to natural surfactant deficiencies [13-15].
Although PFC NP emulsions were clinically effective
in neonates for this application, alternative surfactant
replacement technologies soon emerged and
supplanted their use [16, 17]. Cognizant of the
oxygen-dissolving capacity and high biocompatibility
of PFC emulsions, other investigators continued the
clinical development of PFC NP as artificial blood
substitutes [18]. During this timeframe, PFC NP
research expanded to include GI bowel and general
blood pool contrast uses for CT, MRI, and Doppler
ultrasound [19-23].
The present research considers for the first time
the use of PFC NP administered IT for diagnostic MR
imaging of lung cancer in the Vx2 rabbit model. Given
the high biocompatibility and liquid ventilation
history of perfluorocarbon emulsions, the overarching
hypothesis considered was whether prolonged IT
exposure of lung cancers to PFC NP would afford
deep locally-confined tumor penetration and strong
1H/19F MR signal. The objectives of this study were to:
1) demonstrate that PFC NP can be safely
administered via IT delivery into rabbits with Vx2
lung cancer, 2) measure tumor temporal spatial
differences in 1H T1 mapping and 19F MR imaging
following IT vs. IV delivery of PFC NP with a
clinically relevant scanner, 3) microscopically
characterize PFC NP retention and distribution in
tumor versus normal lung tissue regions, and 4)
compare the biodistribution and bioelimination
pathways of PFC NP given IT versus IV.

Materials and Methods
Chemicals
Unless otherwise listed, all solvents and reagents
were purchased from Aldrich Chemical Co. and used
as received. Phospholipids were purchased from
Avanti Polar Lipids, Inc. (Alabama, USA). Argon gas
(Ultra High Purity: UHP, 99.99%) was used to reduce
oxidation of lipid materials and nanoparticle
emulsions. Dialysis was performed with Spectra/Por
membranes (Cellulose MWCO: 20,000 D, Spectrum
Medical Industries, Inc.) Perfluoro-15-crown-5 ether
(PFCE, C10F20O5) was purchased from Exfluor
Research Corporation (Round Rock, TX) and used as
acquired.

http://www.thno.org
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Preparation of multifunctional
perfluorocarbon nanoparticles

was arrested and O2 content was analyzed at baseline
and every 5 min for 60 min thereafter.

Multifunctional paramagnetic PFC NP (M-PFC
NP) incorporating a fluorescent lipid-anchored dye
were synthesized using microfluidization similar to
prior reports [24-26]. Briefly, the nanoparticulate
emulsions were comprised of 20% (v/v) PFCE, 2%
(w/v) of a surfactant commixture, 1.7% (w/v)
glycerin and water representing the balance. The
surfactant
included
80
mol%
dipalmitoyl
phosphatidylcholine (DPPC), 10 mol% cholesterol, 5
mol% Gd-DTPA-phosphatidylethanolamine (GdDTPA-DPPE), 0.1 mol% 1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-(lissaminerhodamine
B
sulfonyl) (ammonium salt) (16:0 LissRhod PE), and 4.9
mol%1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-gl
ycerol) (sodium salt). The lipids were dissolved in a
mixture of methanol and chloroform, filtered through
a small bed of cotton, evaporated under reduced
pressure using a rotary evaporator at 45 °C to form a
thin film, and then further dried in a vacuum oven (45
°C) for 24 h. The resuspended surfactant was
combined with PFCE and water, then emulsified in a
M110P Microfluidics emulsifier (Microfluidics,
Newton, MA) at 20,000 psi for 4 min. The products
were dialyzed against deionized water using a 20 kDa
MWCO cellulosic membrane. The completed
emulsions were placed in crimp-sealed vials,
blanketed with argon, and stored at 4 °C until use.

Cellular toxicity of perfluorocarbon
nanoparticles on bronchial epithelium

Physical and chemical characterization of
nanoparticles
Hydrodynamic
diameter
distribution,
polydispersity, and zeta potential (ζ) of the PFC
nanoparticles were determined by dynamic light
scattering (DLS) with a Malvern Nano ZS Zetasizer
(Malvern Instruments Ltd, Malvern, UK). All
determinations were made in multiples of five
consecutive measurements. Measurements of ζ were
reproducible to within ±4 mV of the mean value given
by 16 determinations of 10 data accumulations.
Atomic force microscopy measurements (AFM,
Bruker Dimension Icon) were executed in standard
tapping mode. UV/Vis absorption spectra were
performed on a calibrated spectrophotometer
(Perkin-Elmer Lambda 35) at room temperature.
The dissolved oxygen (O2) and the release rate of
O2 in pure water and perfluorocarbon (20% v/v)
solution were measured with a digital multi
parameter meter (Multi 3430 WTW, Germany)
coupled to an O2 sensor (CellOx 325, WTW,
Germany). Pre-test, the samples were ventilated with
slowly bubbling O2 for a predetermined duration. The
measurements of the release rate of oxygen were
performed with O2 ventilation for 5 min, then airflow

The cell viability of normal human bronchial
epithelium BEAS-2B cells (ATCC® CRL-9609™,
Manassas, VA) and lung cancer H520 cells (ATCC®
HTB-182™) were evaluated according to the
manufacturer's instruction using the In-Situ Cell
Death Detection Kit (Roche, Branchburg, NJ, USA).
Cells were seeded in six-well cell culture plates in 2
mL medium with serum under 5% CO2 at 37°C. Cells
were washed with PBS three times then exposed in
the recommended media to 9 mM or 90 mM M-PFC
NP. After 24 h incubation, cells were washed three
times with PBS and then evaluated for apoptosis with
TUNEL diagnostic kit (EMD Millipore, Billerica, MA).
The nuclei were stained with 4',6'-diamidine-2'phenylindole dihydrochloride (DAPI, Sigma Aldrich,
St. Louis, MO). Cells were imaged microscopically
with an Olympus inverted fluorescence microscope
(Olympus (Beijing) Sales & Service Co., Ltd., Beijing,
China).

Flow cytometry assay
Normal epithelium cell BEAS-2B were grown in
the presence of 9 mM M-PFC NPs for 24 h.
Trypsinized cells were harvested and washed in cold
PBS(3×), then isolated by centrifugation (1273 g for 5
min). Single cell suspensions were added to
pre-chilled 75% ethanol and fixed at −20°C overnight.
The cells were rinsed with phosphate buffer,
resuspended, then post-fixed with Cell Cycle Assay
KIT (Biyuntian Company, Shanghai, China). Flow
cytometry was performed using a FACScan (Becton
Dickinson, San Jose, CA) equipped with 488 nm and
633 nm lasers. Samples were gated to exclude debris
and clumps, and electronic compensation was used to
remove residual spectral overlap. The experiment was
repeated in triplicate and data were analyzed using
MultiCycle software WinCycle 32 (Phoenix Flow
Systems, Inc., San Diego, CA).

Clinical pathology
Animal protocols were performed in accordance
with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996) and
were approved and monitored by the Harbin Medical
University and Washington University Animal Care
and Use Committee, respectively.
Clinical pathology was performed on two sets of
KunMing white mice (20-25 g, n=15). Each cohort of
animals
was
divided
into
five
groups
http://www.thno.org
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(n=3/treatment): (1) a sham group; (2) IV M-PFC NP
(2.5 mL/kg, 0.9 g PFC/kg) sacrificed at 24 h; (3)
bilateral IT M-PFC NP (2.5 mL/kg, 0.9 g PFC/kg)
sacrificed at 24 h; (4) IV M-PFC NP (2.5 mL/kg, 0.9 g
PFC/kg) sacrificed at 7 d; or (5) bilateral IT M-PFC NP
(2.5 mL/kg, 0.9 g PFC/kg) sacrificed at 7 d. Blood
samples were submitted for electrolytes, hematology,
liver function and renal function.

Rabbit Vx2 lung xenograft model
The Vx2 tumors, a squamous carcinoma derived
originally from Rous sarcoma virus tumor in rabbits
[27], were surgically implanted into New Zealand
white rabbits (2.0–2.5 kg) in the right lung proximate
to the hilum. Rabbits were fasted 12 h prior to
anesthesia. Atropine (0.05 mg/kg) was injected
intramuscularly 15 min prior to anesthesia followed
by 3% pentobarbital (30 mg/kg) via an indwelling ear
vein catheter. Two or three Vx2 tumor fragments (1
mm3 each) were implanted in the hind limb of a donor
rabbit, and a tumor grew to a desirable size (~20 mm
diameter) in 2 weeks. The tumor was surgically
removed from the donor rabbit under general
anesthesia (as above) and minced into 1 mm3
fragments. The anesthetized recipient rabbit was
positioned supine. The surgical area on the chest was
shaved, prepped and draped. Under CT guidance, an
18 ga needle was percutaneously inserted into the
right lung and positioned in the right lobe proximal to
the hilum. Two fragments of minced Vx2 tumor were
implanted through a 20 ga aspiration needle.
Following extraction of the needle, the incision point
was disinfected and sterile dressings were applied.
Rabbits recovered from anesthesia and were allowed
food and water ad libitum. Two weeks after tumor
implantation, CT (GE Discovery VCT64) was used to
confirm tumor development and size.

MRI Study
Longitudinal relaxation time measurements and
T1 mapping were performed using a GE W750 clinical
3.0T scanner. 19F MR imaging was performed on a
Philips Achieva 3.0T scanner. Relaxivity r1 was
determined by linear fits of R1 versus [Gd].
Particulate concentration was calculated based on the
total volume of NPs divided by single particle
volume(4/3)πr3, where r was nominal particle size
based on DLS testing. A T1w fast spin echo sequence
(FSE) at ambient room temperature was used for
scanning.
Animals for T1 imaging were anesthetized with
2% isoflurane. Vx2 rabbits were administered M-PFC
NPs by IV or IT (n=3, 1 mL/kg, pre-saturated with
O2), using a double-blind protocol. Coronal 1H MR
images were acquired pre-contrast and subsequently
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at 1, 2, 3, 7, 12, 24, 48, 72 h using a facet joint coil. The
MR imaging parameters were: T1w FSE sequence
Echo Train Length:2, TE:9.3 ms, TR:1200 ms, slice
thickness: 5 mm, field of view (FOV): 12×12, matrix
size:288×256, flip angle:90°. For T1 mapping a T1 FSE
sequence with the same parameters as above was
employed except the flip angle was 111° and TEs were
50, 100, 300, 500, 700, 900, 1200, 1500, 1800, 2100, 2500
ms.
For 19F imaging, the rabbits were anesthetized
with Zoletil 50 solution by intramuscular injection
(Virbac (Australia) Pty Limited, Milperra, Australia).
An initial 1H acquisition for anatomical detail was
performed using a fast gradient echo technique with
the body coil (transmit/receive). Matrix: 244×195,
FOV: 140 mm, reconstruction voxel size: 0.625 mm,
TR/TE: 315ms/4.6ms, total scan duration: 02:04,
reconstruction: 320×320, flip angle: 80°, NSA: 2.
Fluorine imaging was performed with a
MC-Rapid-BM-MN coil (RAPID Biomedical GmbH,
Rimpar, Germany) using a 3D fast gradient echo
technique with ultrashort TE (UTE) sequence: FOV:
140 mm, TR/TE: 5.5ms/0.32ms, flip angle: 20°, slice
number: 112, slice thickness: 1.25 mm, total scan
duration: 04:47, reconstructed voxel size: 1.25 mm,
matrix: 112×112, NSA: 2. The fluorine concentration of
the reference phantom for 19F MR imaging was 0.65
M.

Histopathology and immunofluorescence
Male New Zealand white rabbits (~2 kg, n=3)
were anesthetized with intramuscular ketamine and
xylazine. One hind leg was shaved, prepped under
sterile conditions, and infiltrated with Marcaine. A 2-3
mm3 rabbit Vx2 tumor fragment (squamous cell
carcinoma, National Cancer Institute Tumor
Repository, Frederick, MD, USA) was implanted at a
depth of ~0.5 cm through a small incision into the
popliteal fossa. Anatomical planes were closed and
secured with a single absorbable suture. The skin was
sealed with Dermabond skin glue. Animals were
recovered by reversing the effect of ketamine and
xylazine with yohimbine. After ~7 weeks, animals
were imaged with fluoroscopy to confirm metastasis
from the popliteal fossa to the lungs. Animals were
anesthetized with isoflurane to effect, then a catheter
was passed under fluoroscopy into the right lung and
the M-PFC NP dose was instilled (1 mL/kg). The
rabbits recovered and were sacrificed 12 h later for
microscopic examination of the airway and tumor
response to the IT treatment.
The lung and tumor were harvested from the
experimental animals, frozen in OCT and
cryosectioned at 5 μm thickness. Routine staining
including hematoxylin/eosin, CD68, CD31 and
http://www.thno.org
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proliferating cell nuclear antigen (PCNA) were
performed. Nuclei were stained with DAPI. M-PFC
NPs were observed with fluorescence microscopy
(Olympus (Beijing) Sales & Service Co., Ltd., Beijing,
China).

In vivo biodistribution experiment
Biodistribution of PFC NPs (1 mL/kg) delivered
IT or IV was performed in two groups of normal adult
KunMing
white
mice
weighing
20-25
g
(n=3/treatment). At 0.5, 2, 6, 24 and 48 h post
treatment, mice were sacrificed and lung, liver,
kidneys, spleen, heart, brain, intestine were excised
and imaged ex vivo with a Xenogen IVIS spectrum
imaging system (Perkin Elmer, Waltham, MA) using
identical imaging settings (excitation 535 nm,
emission DsRed, exposure time: 1s, binning factor: 2,
F number: 4, FOV: 12.5) for all acquisitions.

Results
Synthesis and physical-chemical
characterization of perfluorocarbon
nanoparticles
M-PFC NPs were comprised of 20% (v/v)
perfluoro-15-crown-5-ether (PFCE), 2% (w/v) lipid
surfactant commixture, which is endogenous to the
lung as surfactants, 1.7% (w/v) glycerin and water
representing the balance. The lipid surfactant
included 80 mol% DPPC, 10 mol% cholesterol, 5 mol%
Gd-DTPA-phosphatidylethanolamine
(Gd-DTPADPPE), 0.1 mol% rhodamine phospholipid, and 4.9
mol% dipalmitoylphosphatidylglycerol (DPPG). The
average nominal hydrodynamic diameter of the
M-PFC nanoparticles determined by DLS was 132±6
nm with polydispersity index 0.14±0.01 and zeta
potential of -42±4 mV. The morphology and height of
the sample obtained by atomic force microscopy in
standard tapping mode demonstrated a soft spherical
particle on a surface with height and width estimates
of 137±16 nm and 62±13 nm, respectively. The MR
magnetic properties of ionic and particulate
relaxivities (r1) of M-PFC were 3.5 mM-1s-1 and 20,450
mM-1s-1, respectively. The use of Gd-DTPA-PE,
provided enhanced 1H r1 relaxivity relative to
Gd-DTPA-bisoleate
(Gd-DTPA-BOA)
studied
previously [28], but the overall 1H r1 was lower than
prior PFC NP that included 20-30 mol%
gadolinium-lipid chelate (Figure 1 and Supplemental
Figure S1).
As previously mentioned, PFCs are chemically
inert molecules with weak intramolecular interactions
that permit significant quantities of many gases,
including oxygen and carbon dioxide, to be physically
dissolved [29, 30]. The capability to dissolve and
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release oxygen was preserved and demonstrated for
the M-PFC NP emulsion as referenced to nanopure
water using a digital multi parameter meter (Multi
3430 WTW, Germany) coupled with an O2 sensor
(CellOx 325, WTW, Germany). Oxygen content in
pure water and M-PFC NP (20%, v/v%) solution were
determined at baseline with slowly bubbled 100%
oxygen preoxygenation (5 min) followed by serial O2
assessments every 5 min for 30 min to measure O2
release (Supplemental Figure S2). The oxygen
content of the M-PFC NP was higher than nanopure
water; however, O2 rate of loss from the emulsion was
rapid and paralleled that of water.
The good biocompatibility and minimal
cytotoxicity of perfluorocarbon emulsions with
phospholipid surfactants were again appreciated
following direct exposure of human bronchial
epithelial (BEAS-2B) and human lung squamous
carcinoma (H520) cells to M-PFC NP at low (9 mM)
and high (90 mM) concentrations. TUNEL staining
revealed no evidence of apoptosis in either cell type at
either concentration. Further, incubation of M-PFC
NP (9 mM) had negligible impact on the cell cycle
progression (stages G0/G1, G2, S) of epithelial cells
over 24 h (Supplemental Figure S3 and S4).
Clinical pathologic circulating biomarkers
including electrolytes, liver function, renal function,
and hematology of healthy mice given IV of M-PFC
NP did not differ obviously from control counterparts
receiving buffered saline. Intratracheal delivery of
M-PFC NP elicited no changes in clinical pathology
markers after 24 h or 168 h (7 d) of exposure
(Supplemental Tables S1 and S2).
1H

and 19F MRI of M-PFC NP following IT or IV
administration

Rabbits bearing 14-day Vx2 tumors received
M-PFC NP (1 mL/kg) via catheter directly into the
right lung IT or by IV through ear vein injection. IT
delivered M-PFC NP remained in the right lung for 72
h with no observed effects on animal behavior or
respiratory function. 1H MR of the rabbit tumors and
nearby muscle tissue following IV and IT M-PFC NP
administration elucidated the localization of the
particles in and around the tumors (Figure 2). Small
increases in tumor R1 following IV M-PFC NP were
detected for 2 h post injection, relating to blood pool
contrast effects, but these changes were not measured
beyond 3 h. IV administration of the M-PFC NP
maximally increased normalized R1 time in nearby
muscle tissue at 30 min post treatment, then the signal
steadily declined toward baseline during the next 12
h. In contradistinction, IT administration of M-PFC
NP markedly increased tumor R1 response
progressively over 12 h and this strong enhancement
http://www.thno.org
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persisted for 72 h. These data suggested that the
M-PFC NP given IT accumulated slowly and
remained confined locally in the lung Vx2 tumors;
whereas, the same particles given IV failed to
effectively extravasate into the cancer. Moreover, the
strong increase in tumor 1H R1 with M-PFC NP given
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IT suggest that the payload of particles accumulated
in the lesion was large, particularly since the 1H
relaxivity of the M-PFC NP studied was low. These
superior MR data clearly suggest a theranostic
potential for IT PFC NP administration in lung cancer.

Figure 1. Physicochemical characterization of multifunctional perfluorocarbon nanoparticles. (A) Schematic representation of the structure of M-PFC NPs. (B)
UV-Vis absorption spectra of PFC NPs with and without inclusion of rhodamine-PE. (C) DLS nominal hydrodynamic diameter of the multifunctional PFCs in aqueous
solution was ~132 nm with stability across a wide pH range (4-12). (D) Particle morphology and height obtained from AFM. (E) T1w MR images. (F) T1map images
as a function of Gd ion concentration; (G)19F phantom images for decreasing PFC concentration (From 1 to 5: 332, 265, 199, 132, 66 mM); 1H R1 as a function of (H)
Gd ion and (I) particulate concentration. Slopes provide r1; (J) Linear fit between 19F signal intensity and PFC concentration.

http://www.thno.org
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Figure 2. Representative images of in vivo T1w MRI after IT delivery of M-PFC NPs. (A) T1 color mapped MR images normalized to baseline; T1w MR images of (B)
sagittal view, (C) coronal view, (D) transverse view; (E) and (F), the quantitative calculation of the enhancement at tumor(E) and muscle(F) sites and their specific value
of R1 after different administration points (the error bars represent the standard deviations of three independent measurements of the same group).

Pulmonary 19F imaging of the tumor with the
M-PFC NP using the same IT delivery protocol
mirrored the marked 1H R1mapping results closely.
19F signal was visually prominent in the Vx2 tumor at
1 h and this strong signal persisted over 72 h, as
shown in Figure 3. 19F imaging with paramagnetic
PFC nanoparticles is inherently less sensitive than 1H
imaging due to the relative paucity of fluorine atoms
per voxel and lower NMR sensitivity of 0.83.
However, the magnitude of the 19F signal can be
enhanced when gadolinium-lipid chelates, such as
Gd-DTPA-BOA, that position the metal very close to
the PFC core are included in the lipid surfactant [22,
31-33]. In the present study the low level of
Gd-DTPA-PE placed the metal further away from the
PFC molecules into the surrounding water, providing
minimal benefit to the 19F signal.
M-PFC NP utilized perfluorocrown ether (PFCE)
(15:5) to maximize 19F signal by increasing the number
of iso-resonant fluorine atoms and to offset the
possibility that the particles localizing in the tumor
would be too few to detect. Yet, the tumor 1H R1
increase achieved with M-PFC NP was very high, as
was the 19F signal. These data showed that intact
M-PFC NP entered the tumor with the surfactant and
PFC core maintained together.

Microscopy of implanted and metastatic Vx2
lung cancer
Consistent with previous studies in which
paramagnetic PFC nanoparticles, both targeted and
non-targeted, were administered intravenously to
rabbits bearing Vx2 tumors in the popliteal
fossa[24-26], rabbits with pulmonary tumors given
fluorescent M-PFC NP IV showed negligible
permeation of the particles into the cancer (Figure 4).
This result corroborated the lack of persistent MR
signal appreciated in the lung following M-PFC NP IV
treatment. In contradistinction, microscopy of the
pulmonary Vx2 cancer 72 h after IT M-PFC NP
revealed deep penetration into the tumor with very
dense particle coating around the tumor and stromal
cells. By comparison, adjacent tumor-free lung tissue
was non-consolidated and showed no evidence of
fluorescent M-PFC NPs in the parenchyma (Figure
4A). The surfactant fluorescent dye, which could be
considered as a surrogate therapeutic biomarker,
labeled most of the cells in the lesion.
A second cohort of rabbits (n=3) with Vx2 tumor
implanted in the popliteal fossa metastasized
spontaneously to the lung in 7 weeks. Fluorescent
M-PFC NP were delivered IT into the right bronchus
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and remained for 12 h. Following sacrifice, the
pulmonary airways were excised, sectioned and
reviewed microscopically. Segments of the airway
without Vx2 tumor metastases were devoid of
nanoparticles and without inflammation. In other
regions, metastatic tumors were observed adjacent to
the airways and fluorescent M-PFC NP were
distributed densely throughout the tumor (Figure
4B). The surrounding airway epithelium had minimal
fluorescent dye uptake. Possibly the mucous barrier
and ciliary clearance mechanism that protectively
transports foreign particles from the lungs constituted
a barrier between the particle lipid surface and
epithelial cell membrane.
In both models, IT M-PFC NP penetrated deep
into the Vx2 tumors and transferred the fluorescent
lipid dye to cancer and other cells seen. Although the
M-PFC NP administered IT were not targeted, their
dense accumulation and prolonged contact with cells
in the tumor led to a similar end result. Interestingly,
the central necrotic cores of these metastatic tumors
were devoid of fluorescent M-PFC NP, suggesting a
difference in lung tumor development between
implanted cancer pieces and spontaneously
metastatic cells.

Biodistribution of nanoparticles given
intratracheal versus intravenous
Tissue biodistribution study of fluorescent
M-PFC NP (Figure 5) was studied in mice using a
Xenogen IVIS imaging system, recognizing that
rodents, unlike humans or rabbits, uniquely excrete
nanoparticles rapidly into the small intestine via the
biliary system [34]. As has been long appreciated for
PFC NP [35, 36], M-PFC NPs given IV distributed to
the spleen, liver and intestine at 30 min with little or
no appreciable signal in the heart, lung or brain,
which is also consistent with previous studies[37].
Between 6 and 24 h, IV M-PFC NP concentrations in
the liver and spleen declined, with the fluorescence
signal shifting to the bowel. By comparison, IT M-PFC
NP distributed into the airway and lung with no
systemic accumulation observed in the liver, spleen,
or intestine over the course of the study. These data
are consistent with MR imaging data in rabbits and
suggest that IV administered M-PFC NP do not easily
extravasate into tumors [24-26]; conversely IT
administered particles were constrained within the
tumor. Ultimately, bioelimination of PFC NP, whether
administered IV or IT, eventually occurs through
pulmonary exhalation of volatilized PFC [38], with
the surfactant lipid components metabolized or
excreted from the body. The benign PFC expiratory
clearance mechanism combined with the potential to
dissolve and locally release inspired oxygen from
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within the tumor suggests an advantage for IT PFC
NP.

Discussion
Lung cancer often presents in its late stages with
cough and hemoptysis associated with tumor erosion
into the airway. The prognosis for these patients is
grim and palliative therapy often has limited benefit.
Yet, in these poor prognosis situations, tumor
disruption through the airway epithelial barrier may
offer uncommon drug access into the lesion via
intratracheal
delivery.
Typically,
pulmonary
inhalation of drugs and particles, whether therapeutic
or via environmental exposure, can elicit pulmonary
inflammation and respiratory dysfunction. Although
intended for local delivery, IT delivery of
nanoparticles frequently permeates further into the
circulation, decreasing the level of therapy retained in
the lung and increasing the risk of systemic off-target
effects [39]. As an example, the orotracheal delivery of
ultrasmall gadolinium oxide nanoparticles was
shown to effectively penetrate into lung tumor but
then continued to diffuse into the circulation and
subsequently collected in the kidney [40]. Some
inhaled particles, such as large iron oxide
nanoparticles (100 nm), elicit strong inflammatory
responses and elevated chemokine secretions [41].
Titanium oxide (TiO2) nanoparticles, known to cause
renal fibrosis when injected systemically, were found
to elicit dose-dependent pathological changes in the
kidney via IT delivery as well as emphysema-like
lung injury [42, 43]. Clearly, the intended localized
high dose and safety benefits attributed to IT
nanoparticle delivery can be compromised when the
minute size of these agents permits penetration into
the systemic circulation or when the chemical
composition is inflammatory.
Perfluorocarbons
inherently
have
high
biocompatibility and a capacity to dissolve oxygen
that
was
dramatically
demonstrated
by
liquid-ventilation, i.e., liquid breathing, in rodents in
1966 [44]. Continued research with PFC nanoparticles
led to a seminal clinical demonstration of improved
pulmonary function in neonatal infants suffering with
respiratory distress syndrome in 1996 [15]. These
fragile neonates receiving intratracheal PFC NP
experienced improved respiratory function with
negligible adverse effects. Over the last 25 years, PFC
NPs have been extensively explored in both
preclinical and clinical realms. Applications involving
IV administration of PFC NP include blood pool
imaging, inflammation imaging, cell tracking,
thrombus detection and treatment, angiogenesis
imaging and drug delivery in cancer, atherosclerosis,
and rheumatoid arthritis models, etc. [45-48].
http://www.thno.org
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Figure 3. Dynamic monitoring of 19F-MR enhancement at different time points post IT delivery of the M-PFC NPs. Image slices were acquired at different time points
and examples selected to depict similar cardiothoracic regions.

Figure 4. (A) Microscopy of rabbits receiving in situ surgical implantation, following IT treatment. The upper row represents the typical images harvested from lung
tumor 72 h after MR study. Fluorescence microscopy images of tumor tissue with DAPI stained nuclei (blue) and Rhod B(red) fluorescence from M-PFC NP. Normal
tissue from the same rabbit with no M-PFC NP signal (scale bars = 100 μm). (B) Microscopic imaging of metastatic carcinoma Vx2 tumor model. While the left lung
showed low tumor burden, the right lung had tumors with high density M-PFC NP signal (red) around the tumor periphery. H&E staining of lung tumor (white box,
expanded) revealed a necrotic core (arrows), which is also indicated by a star in the lower magnification image. CD68 macrophages were noted around the tumor
capsule. PECAM stained blood vessels were also mostly peripheral around the tumor capsule (arrows). Proliferating PCNA positive cells were best observed within
the metastatic tumor and around its capsule.
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Figure 5. The biodistribution of M-PFC nanoparticles with time-dependent isolated organs as seen using the NIRF imaging technique. (A) Intratracheal delivery; (B)
intravenous injection. (scale bars=1 cm)

In the present study, the high biocompatibility,
ideal size, oxygen dissolving capacity and natural
bioelimination via exhalation contributed to the
success of M-PFC NP in the Vx2 rabbit lung tumor
model. As evidenced by 1H and 19F MR imaging, the
IT M-PFC NP penetrated into the growing Vx2 tumor,
slowly and progressively over 12 h and persisted for
72 h. The magnitude and persistence of M-PFC NP via
intratracheal delivery into the tumor was dramatically
better than the minimal and transient MR T1 signal
response noted at 2 h following IV injection.
Moreover, IT M-PFC NP were essentially confined to
the cancer, lung and airways, whereas, the
biodistribution of IV M-PFC NP extended beyond
with systemic accumulation in the liver and spleen.
Extravascular distribution of nanoparticles into
tumors following intravenous injection remains a
significant barrier to the clinical translation of
nanotechnology [49]. Although some particles are
capable of penetrating beyond the circulation and into
the tumor, inhomogeneous distribution within the
lesion with large portions of the cancer unaffected is
common [50]. Intratumoral delivery by IT M-PFC NP
had very homogeneous distribution, excluding only
the necrotic regions. In each animal, the IT fluorescent

M-PFC NP densely coated the tumor cells and their
microenvironment, which was evidenced by the
strong T1 shortening and prominent 19F signals
measured with MRI.
The prolonged tumoral persistence of the 19F and
1H signal administered IT also reflects the very long
biological half-life of PFCE (250d, 9.4T) as compared
with perfluorooctylbromide (PFOB, 12d, 9.4T) used
previously in clinical studies [51]. In humans, the
biological half-life estimate for PFOB is typically cited
as 3-4 d, while PFCE intrapulmonary persistence is
clinically too long (>60 d) [52]. Recently, 19F
neovascular molecular imaging studies at 3T (clinical)
utilized αvβ3-targeted PFOB nanoparticles to detect
the sparse αvβ3-intergrin expression of pulmonary
neovasculature in rat models of acute lung ischemia
and asthma [53-55]. These data considered in
combination with the strong serial 1H/19F data
presented in this report suggest that substitution of
PFCE with PFOB would not compromise the
theranostic potential of the nanoplatform approach.
Although the treatment of lung cancer was
beyond the scope of this proof-of-concept imaging
study, the potential for effective lung cancer treatment
with IT delivered PFC NP was suggested by the broad
http://www.thno.org
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transfer of rhodamine-lipid dye to intratumoral cells
observed with microscopy. The formation of these
irreversible lipid fusion complexes facilitates the
delivery of drug payloads into cells via "contact
facilitated drug delivery" [56]. Moreover, the dense
delivery of continuously oxygenated PFC NP within
an otherwise hypoxic tumor may offer potent
radio-sensitization for focal radiation or PDT therapy
guided by 19F-MRI [57-60]. The use of therapeutic
drugs in combination with IT administered PFC NP
may be a highly effective delivery approach for lung
cancer warranting further research.

Conclusion
Lipid-encapsulated
M-PFC
NP
were
administered via intratracheal delivery into rabbits
bearing pulmonary Vx2 tumors implanted surgically
or formed by metastasis. Enhanced intratumoral
penetration of intact paramagnetic PFC nanoparticles
by IT administration was demonstrated for the first
time by 19F and 1H MR using clinical 3T scanners. The
PFC particles persisted for over 72 h in vivo without
adverse effects on rabbit behavior or respiration.
Fluorescence microscopy corroborated that IT M-PFC
NP permeated deeply and distributed widely
throughout the tumors. In contradistinction, IV
M-PFC NP did not extravasate into the lung cancers
and provided much lower transient tumor contrast
enhancement, consistent with a blood pool effect. By
the IT route, M-PFC NP uptake was confined to the
Vx2 cancer without significant permeation into the
general circulation. By comparison, IV administration
of M-PFC NP resulted in transient enhancement of
highly vascular muscle tissues with typical RES
clearance by the liver and spleen. This
proof-of-concept study returns the focus of PFC NP
delivery
from
intravenous
applications
to
intratracheal use to address the unmet challenges
posed by lung cancer.
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